Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial | Zendy

Kathy S. Albain | Zendy; Robert J. Gray | Zendy; Della Makower | Zendy; Amir Faghih | Zendy; Daniel F. Hayes | Zendy; Charles E. Geyer | Zendy; Elizabeth Claire Dees | Zendy; Matthew P. Goetz | Zendy; John A. Olson | Zendy; Tracy Lively | Zendy; Sunil Badve | Zendy; Thomas J. Saphner | Zendy; Lynne I. Wagner | Zendy; Timothy J. Whelan | Zendy; Matthew J. Ellis | Zendy; William C. Wood | Zendy; Maccon Keane | Zendy; Henry Gómez | Zendy; Pavan S. Reddy | Zendy; Timothy F. Goggins | Zendy; Ingrid A. Mayer | Zendy; Adam Brufsky | Zendy; Deborah Toppmeyer | Zendy; Virginia Kaklamani | Zendy; Jeffrey L. Berenberg | Zendy; Jeffrey S. Abrams | Zendy; George W. Sledge | Zendy; Joseph A. Sparano | Zendy

Open Access

Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial

Author(s) -

Kathy S. Albain,

Robert J. Gray,

Della Makower,

Amir Faghih,

Daniel F. Hayes,

Charles E. Geyer,

Elizabeth Claire Dees,

Matthew P. Goetz,

John A. Olson,

Tracy Lively,

Sunil Badve,

Thomas J. Saphner,

Lynne I. Wagner,

Timothy J. Whelan,

Matthew J. Ellis,

William C. Wood,

Maccon Keane,

Henry Gómez,

Pavan S. Reddy,

Timothy F. Goggins,

Ingrid A. Mayer,

Adam Brufsky,

Deborah Toppmeyer,

Virginia Kaklamani,

Jeffrey L. Berenberg,

Jeffrey S. Abrams,

George W. Sledge,

Joseph A. Sparano

Publication year - 2020

Publication title -

jnci journal of the national cancer institute

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.797

H-Index - 356

eISSN - 1460-2105

pISSN - 0027-8874

DOI - 10.1093/jnci/djaa148

Subject(s) - breast cancer , her2 negative , hormone receptor , oncology , ethnic group , medicine , race (biology) , randomized controlled trial , hormone , cancer , biology , metastatic breast cancer , sociology , anthropology , botany

Black race is associated with worse outcomes in early breast cancer. We evaluated clinicopathologic characteristics, the 21-gene recurrence score (RS), treatment delivered, and clinical outcomes by race and ethnicity among women who participated in the Trial Assigning Individualized Options for Treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research